MOPEVACLAS vaccine candidate for Lassa fever enters clinical trials

After more than 20 years of research on arenaviruses, an Institut Pasteur team led by Sylvain Baize has developed an original vaccine platform known as MOPEVAC, which will strengthen the Institut Pasteur's pandemic preparedness initiatives. A Phase Ia clinical trial led by a research team at the Institut Pasteur is set to begin for the platform's first vaccine candidate, which targets Lassa fever, a hemorrhagic fever responsible for thousands of deaths worldwide each year. In the long term, the MOPEVAC platform will enable scientists to respond to the emergence of new viruses with effective candidate vaccines aimed at pathogens with high mortality rates. The MOPEVAC clinical trials are funded by the France 2030 program as part of the "Emerging infectious diseases and CBRN threats" strategy. They are led by the French Health Innovation Agency and operated on behalf of the French government by Bpifrance, which also supported the preclinical trials.
 
Find out more